Clinical trials: Difficile
Clostridium Difficile
Chlorhexidine Bathing Effect on Clostridium Difficile Rates
Clostridium difficile (C. diff.) infections, whether nosocomial or community borne, may present with profound diarrhea, especially in those patients receiving antibiotics.
- Trial name
- NCT02502682
- Testing
- Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Jared Brooks
Clostridium Difficile, Inflammatory Bowel Diseases
Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.
The objective of this study to evaluate the seroprevalence of anti-bodies against C. difficile toxins A and B and the asymptomatic carriage of C.
- Trial name
- NCT03889808
- Testing
- Determination of serum anti-toxin Abs for C. difficile
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari de Bellvitge
Healthcare Associated Infection, Clostridium Difficile Infection
Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection
The objective is to conduct a prospective, sham controlled, double-blinded, interventional crossover trial to compare standard terminal cleaning plus PX-UV (intervention) with standard terminal cleaning plus sham PX-UV (control)…
- Conditions
- Healthcare Associated Infection, Clostridium Difficile Infection, Infection Due to Multidrug Resistant Bacteria
- Trial name
- NCT03349268
- Testing
- Pulsed xenon ultraviolet (PX-UV) Device
- Where
- United States
- Volunteers
- 25,732 people
- Sponsor
- University of Michigan
Diarrhea Due to Clostridium Difficile
Host Immune Response to Clostridium Difficile Infection (ICD)
Clostridium difficile is responsible for up to 25% of reported antibiotic associated diarrhea cases and virtually all cases of pseudomembranous colitis (PMC). The clinical spectrum of C.
- Trial name
- ICD (NCT02440438)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Hospices Civils de Lyon
Clostridium Difficile Infection
Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
The purpose of this research is to investigate the efficacy of transplanting screened donor fecal material in treating patients with recurrent Clostridium difficile infection.
- Trial name
- FMT (NCT02326636)
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of California, Irvine
C. Difficile Infection, Cancer
Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection
The purpose of this study is to test the safety of FMT in patients with C. difficile and cancer. In previous other studies, FMT has been shown to cure C.
- Trial name
- NCT02770326
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clostridium Difficile Infection
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
This study will investigate whether: 1) treatment with MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium difficile infection (CDI) recurrence as compared to treatment with MK-6072 or…
- Trial name
- MODIFY I (NCT01241552)
- Testing
- MK-3415, MK-6072, MK-3415A
- Volunteers
- 1,452 people
- Sponsor
- Merck Sharp & Dohme LLC
Clostridium Infections
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
- Trial name
- NCT00384527
- Testing
- Nitazoxanide, Vancomycin
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- Romark Laboratories L.C.
Clostridium Difficile Infection
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
The purpose of the study is to determine the safety and efficacy of Fecal Microbiota Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI) as compared to standard antibiotic therapy.
- Trial name
- NCT02255305
- Testing
- FMT, Antimicrobials
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Endeavor Health
C. Difficile, C. Difficile Infection
Clostridioides Difficile Controlled Human Infection Model
This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea.
- Conditions
- C. Difficile, C. Difficile Infection, Controlled Human Infection
- Trial name
- CloDiCHI (NCT06702345)
- Testing
- encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Clostridium Difficile Infection, Ulcerative Colitis
Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis
Fecal Microbiota Transplantation will be offered to eligible C. difficile patients (does not require Investigational New Drug designation) and to eligible ulcerative colitis or indeterminate colitis patients as Investigational…
- Conditions
- Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
- Trial name
- FMT (NCT03268213)
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stony Brook University
Clostridium Difficile Associated Diarrhea (CDAD)
A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)
This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of oral doses of surotomycin (CB-183,315) administered for 14 consecutive days in healthy males and females.
- Trial name
- NCT02835118
- Testing
- Surotomycin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diarrhoea
Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea
The investigators aim to investigate whether the routine use of the probiotic formulation VSL#3 co-prescribed with antibiotics reduces the incidence of both Antibiotic associated diarrhoea and Clostridium Difficile associated…
- Trial name
- NCT00973908
- Testing
- VSL#3
- Where
- 5 sites in United Kingdom
- Volunteers
- 231 people
- Sponsor
- National Health Service, United Kingdom
Clostridium Difficile
Intestinal Lavage for the Treatment of Severe C. Difficile Infections
Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and supportive care, with surgical intervention reserved for patients with significant systemic toxicity or perforation.
- Trial name
- NCT02466698
- Testing
- Intestinal Lavage, Vancomycin, PEG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Clostridioides Difficile Infection
LMN-201 for Prevention of C. Difficile Infection Recurrence
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
- Trial name
- NCT05330182
- Testing
- LMN-201
- Where
- 15 sites in United States
- Volunteers
- 375 people
- Sponsor
- Lumen Bioscience, Inc.
Clostridium Difficile Infection
Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.
- Trial name
- NCT02237859
- Testing
- Vancomycin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Corewell Health West
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care…
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT), Comparative Effectiveness of CDI Treatments
- Trial name
- STOP-CDI (NCT07120490)
- Testing
- FMT (fecal microbiota transplantation), Fidaxomicin, Vancomycin (VAN) treatment
- Volunteers
- 424 people
- Sponsor
- Medical University of Warsaw
Clostridium Difficile Infection
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
MK-3415A is the combination of monoclonal antibodies to Clostridium (C.) difficile toxin A (MK-3415) and toxin B (MK-6072). This study will investigate whether: 1) treatment with MK-6072 or MK-3415A in addition to standard of…
- Trial name
- MODIFY II (NCT01513239)
- Testing
- MK-6072, MK-3415A, SOC
- Volunteers
- 1,203 people
- Sponsor
- Merck Sharp & Dohme LLC
Clostridial Infection, Dysbiosis
Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)
Multi-center, randomized, placebo controlled, partially blinded trial comparing the safety and efficacy of fecal microbiota transplantation versus placebo both delivered by rectal enema in subjects 18 years of age or older with…
- Conditions
- Clostridial Infection, Dysbiosis, Probiotic Therapy
- Trial name
- NCT03548051
- Testing
- Fecal Microbiota Transplantation (FMT), Saline
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection
FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness, associated with significant morbidity and mortality and has a high burden on health-care system.
- Trial name
- NCT02570477
- Testing
- Fecal Microbiota Transplantation, Vancomycin
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong